Erythropoietin and erythropoiesis: Polycythemias due to disruption of oxygen homeostasis

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Prchal, Josef T ^a   Pastore, Yves D ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Hopital de la Chaux de Fonds   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; BISPHOSPHOGLYCERATE MUTASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HEMOGLOBIN; LOSARTAN; OXYGEN;

ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE MARKER; ERYTHROCYTOSIS; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; OXYGEN TRANSPORT; PARANEOPLASTIC SYNDROME; PATHOGENESIS; POLYCYTHEMIA; POLYCYTHEMIA VERA; SCREENING TEST; X CHROMOSOMAL INHERITANCE;

EID: 4043124668     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200434     Document Type: Article

References (44)

1. Jelkmann W, Fandrey J, Wiedemann G. Immunoreactive erythropoietin in the anemia of non-renal chronic diseases. Biomed Biochim Acta 1990; 49: S265-S270.
2. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14: 1983-1991.
3. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993; 90: 4304-4308.
4. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268: 21513-21518.
5. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin N Am 1994; 8: 863-864.
6. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 2002; 99: 13459-13464.
7. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
8. Maxwell PH. HIF-1's relationship to oxygen: simple yet sophisticated. Cell Cycle 2004; 3: 156-159
9. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and response glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386: 403-407.
10. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-162.
11. Adelman DM, Maltepe E, Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 1999; 13: 2478-2483.
12. Pastore YD, Liu E, Divoky V, Ponka P, Semenza G, Prchal JT. The erythropoietic defect in HIF-1 alpha -/- is primarly related to disrution in iron metabolism. Blood 2003; 102: 2116 (abstract).
13. Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses)and thrombocytosis. Hematol Oncol Clin N Am 2003; 17: 1151-1158, VI.
14. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton III LJ. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994; 47: 89-93.
15. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-351.
16. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
17. Prchal JF, Adamson JW, Steinmann L, Fialkow PJ. Human erythroid colony formation in vitro: evidence for clonal origin. J Cell Physiol 1976; 89: 489-492.
18. Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 1974; 290: 1382.
19. Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982-1991.
20. Temerinac S, Klippel S, Strunck E, Roder S, Lubbert M, Lange W et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000; 95: 2569-2574.
21. Dai C, Krantz SB. Increased expression of the INK4a/ARF locus in polycythemia vera. Blood 2001; 97: 3424-3432.
22. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-236.
23. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas APC et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102: 1869-1871.
24. Najfeld Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002; 119: 558-566.
25. Kralovics R, David W, Stockton DW, Josef T, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102: 3793-3796.
26. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Nat Acad Sci USA 1993; 90: 4495-4499.
27. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90: 2057-2061.
28. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001; 68: 115-121.
29. Jedlickova K, Stockton DW, Prchal JT. Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2. Blood Cells Mol Dis 2003; 31: 327-331.
30. Poliakova LA. [Familial erythrocytosis among the residents of the Chuvash ASSR]. Probl Gematol Pereliv Krovi 1974; 19: 30-33.
31. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood 1997; 89: 2148-2154.
32. Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA, Miasnikova GY et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis 2002; 28: 57-62.
33. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32: 614-621.
34. Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101: 1591-1595.
35. Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Gene 2003; 73: 412-419.
36. Percy MJ, McMullin MF, Jowitt SN, Potter M, Treacy M, Watson WH et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood 2003; 102: 1097-1099.
37. Percy MJ, Beard ME, Carter C, Thein SL. Erythrocytosis and the Chuvash von Hippel-Lindau mutation. Br J Haematol 2003; 123: 371-472.
38. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL et al. Congenital disorder of oxygen-sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004; Jan 15 (Epub ahead of print).
39. Liu E, Percy MJ, Amos CI, Guan Y, Shete S, Stockton DW et al. The worldwide distribution of the VHL 598C> T mutation indicates a single founding event. Blood 103; 2004: 1937-1949.
40. Lichtman MA, Murphy, MS, Adamson JW. Detection of mutant hemoglobins with altered affinity for oxygen. A simplified technique. Ann Intern Med 1976; 84: 517-520.
41. Richard S, Croisille L, Yvart J, Casadeval N, Eschwege P, Aghakhani N et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002; 99: 3851-3853.
42. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Linidau protein. Blood 2002; 99: 3562-3565.
43. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II facilitates erythropoietin mediated proliferation of normal early erythroid progenitors. J Clin Invest 1997; 115: 508-522.
44. Hwang SJ, Lee SD, Wu JC, Chang CF, Lu CL, Tsay SH et al. Clinical evaluation of erythrocytosis in patients with hepatocellular carcinoma. Chung Hua I Hsueh Tsa Chih (Taipei) 1994; 53: 262-269.